Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06320951
Other study ID # 300012681
Secondary ID Pending
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date May 1, 2025
Est. completion date April 30, 2029

Study information

Verified date May 2024
Source University of Alabama at Birmingham
Contact Nehal Vekariya, MS
Phone 2059347173
Email nvekariya@uabmc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study investigates the potential of vericiguat, a soluble guanylate cyclase stimulator, to improve cardiometabolic health in obese Black individuals with insulin resistance by directly enhancing cyclic guanosine monophosphate (cGMP) activity. Given that this population has been shown to have lower cGMP activity and the association of lower cGMP activity with increased cardiometabolic disease risk, the proposed study hypothesizes that augmenting cGMP activity in obese individuals will improve insulin sensitivity and energy expenditure. This study is a placebo-controlled randomized trial involving 200 Black obese participants with insulin resistance, assessing the effects of vericiguat on insulin sensitivity, resting, and exercise-induced energy expenditure over 12 weeks. Additionally, it will explore changes in brown adipose tissue and gene expression related to energy metabolism in white adipose tissue, aiming to provide insights into how increasing cGMP activity may improve cardiometabolic health in Black obese individuals.


Description:

Obese Black individuals have a higher prevalence of insulin resistance, which is linked to an elevated risk of cardiometabolic diseases and cardiovascular disease. The reasons behind the increased insulin resistance in this group are not fully understood. Key to regulating glucose metabolism and the overall balance of energy, the cyclic guanosine monophosphate (cGMP) pathway is crucial for maintaining cardiometabolic health. Research indicates that both Black race and obesity are associated with reduced levels of upstream regulators of cGMP activity, including natriuretic peptides (NPs) and nitric oxide (NO). This reduced level of NPs and NO predisposes Black obese individuals to decreased cGMP activity, potentially contributing to the higher occurrence of cardiometabolic diseases seen in this population. Vericiguat, a drug that stimulates the soluble guanylate cyclase, thereby enhancing cGMP activity independently of NO, presents a novel approach to improving cardiometabolic health in those most at risk due to low cGMP activity. This study hypothesizes that directly augmenting cGMP levels with vericiguat will improve cardiometabolic health parameters including insulin sensitivity and energy expenditure in Black obese adults with insulin resistance. Investigators plan to execute a placebo-controlled randomized trial targeting Black obese participants with insulin resistance to examine whether vericiguat can (1) improve insulin sensitivity and (2) increase resting energy expenditure. For the first aim, Investigators aim to enroll 200 Black obese (BMI≥30 kg/m^2) individuals with a HOMA-IR of ≥2.5, randomizing them to either vericiguat 10 mg once daily or a placebo once daily in a double-blind setup for 12 weeks. Investigators will assess improvements in insulin sensitivity through euglycemic hyperinsulinemic clamp and compare the results between the vericiguat and placebo groups after 12 weeks. For the second aim, Investigators will evaluate changes in resting and exercise energy expenditure across both groups over the same period. An exploratory objective will investigate changes in brown adipose tissue volume and activity using PET-MRI, as well as UCP1 gene expression in white adipose tissue, in a subset of 100 participants after 12 weeks of vericiguat treatment. This will offer insights into the mechanisms by which cGMP augmentation may facilitate improvements in cardiometabolic health. By focusing on the direct enhancement of cGMP activity in Black obese individuals, this study proposes a novel targeted therapeutic strategy aimed at improving cardiometabolic health and addressing the increasing prevalence of cardiometabolic disease in the Black population.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date April 30, 2029
Est. primary completion date April 30, 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Adults: Age more than or equal to 18 years of age - Self-identified race/ethnicity as African-American or Black - BMI = 30 kg/m2 - HOMA-IR = 2.5 - Blood pressure: 120-160/80-100 mmHg (untreated or 1 week of washout in those treated with up to two classes of antihypertensives) - Willing to adhere to study protocol Exclusion Criteria: - Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence) - Have any past or present history of cardiovascular diseases (stroke, myocardial infarction, heart failure, transient ischemic attack, angina, seizure or cardiac arrhythmia) - BP more than 160/100 mmHg or those treated with three or more classes of antihypertensives - BMI >45 kg/m2 - History of diabetes or fasting plasma glucose >=126 mg/dL or HbA1C>=6.5% or prior treatment with antidiabetics - Estimated GFR < 60 ml/min/1.73 m2; albumin-creatinine ratio =30 mg/g - Hepatic Transaminase (AST and ALT) levels >3x the upper limit of normal - Significant psychiatric illness (assessed using validated MINI questionnaire) - Anemia (men, Hb<13 g/dL; women, Hb <12 g/dL) - Inability to exercise on a treadmill

Study Design


Intervention

Drug:
Vericiguat 10 MG
The subject will be randomized, in a double-blind manner to vericiguat 10 mg once daily for a period of 12 weeks.
Other:
Placebo
The subject will be randomized, in a double-blind manner to placebo once daily for a period of 12 weeks.
Insulin Sensitivity Test
An assessment of the insulin sensitivity will be done using the Euglycemic Hyperinsulinemic Clamp, at baseline and after 12 weeks of pharmacological interventions.
Resting Energy and Exercise Energy Expenditure Assessment
Each participant's Energy Expenditure will be determined using a metabolic cart, at baseline and after 12 weeks of pharmacological interventions.
White Adipose Tissue Biopsy
Participants who consent to participate in the exploratory aim will undergo WAT biopsy to assess UCP1 gene expression from the collected biospecimens, at baseline and after 12 weeks of pharmacological interventions.
MRI-PET Scan for Brown Adipose Tissue Volume Assessment
Participants who consent to participate in the exploratory aim will undergo PET/MR to BAT volume at baseline and after 12 weeks of pharmacological interventions.

Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in insulin sensitivity after vericiguat in Black obese individuals with insulin resistance. The difference in change in insulin sensitivity between baseline and post-intervention between two arms. 12 weeks
Primary Change in resting energy expenditure (REE) after vericiguat in Black obese individuals with insulin resistance. The difference in change in REE between baseline and post-intervention between two arms. 12 weeks
Secondary Change in BAT volume after vericiguat in Black obese individuals with insulin resistance. The difference in change in BAT volume between baseline and post-intervention between two arms. 12 weeks
Secondary Change in BAT activity after vericiguat in Black obese individuals with insulin resistance. The difference in change in BAT activity between baseline and post-intervention between two arms. 12 weeks
Secondary Change in UCP1 gene expression after vericiguat in Black obese individuals with insulin resistance. The difference in change in UCP1 gene expression between baseline and post-intervention between two arms. 12 weeks
Secondary Change in exercise energy expenditure (EEE) after vericiguat in Black obese individuals with insulin resistance. The difference in change in EEE between baseline and post-intervention between two arms. 12 weeks
Secondary Change in glycosylated hemoglobin (HbA1C) after vericiguat in Black obese individuals with insulin resistance. The difference in change in HbA1C between baseline and post-intervention between two arms. 12 weeks
Secondary Change in Body Mass Index (BMI) after vericiguat in Black obese individuals with insulin resistance. The difference in change in BMI between baseline and post-intervention between two arms. 12 weeks
Secondary Change in Total Cholesterol (TC) after vericiguat in Black obese individuals with insulin resistance. The difference in change in TC between baseline and post-intervention between two arms. 12 weeks
Secondary Change in low-density lipoprotein-cholesterol (LDL-C) after vericiguat in Black obese individuals with insulin resistance. The difference in change in LDL-C between baseline and post-intervention between two arms. 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2